yn_bt: MS Patients Have Significant And Sustained Reduction In Disability And Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif(R)

2008年10月28日火曜日

MS Patients Have Significant And Sustained Reduction In Disability And Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif(R)

MS Patients Have Significant And Sustained Reduction In Disability And Risk Of Relapse On Alemtuzumab Versus Approved Therapy, Rebif(R)

アレムツズマブ、CD52、MS、Bayer

0 件のコメント:

コメントを投稿

登録: コメントの投稿 (Atom)